Canada · Delayed Price · Currency is CAD Sharp Therapeutics Statistics
Total Valuation
TSXV:SHRX has a market cap or net worth of CAD 27.37 million. The enterprise value is 27.82 million.
| Market Cap | 27.37M |
| Enterprise Value | 27.82M |
Important Dates
The next estimated earnings date is Thursday, September 3, 2026.
| Earnings Date | Sep 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:SHRX has 30.08 million shares outstanding. The number of shares has increased by 227.37% in one year.
| Current Share Class | 30.08M |
| Shares Outstanding | 30.08M |
| Shares Change (YoY) | +227.37% |
| Shares Change (QoQ) | -7.26% |
| Owned by Insiders (%) | 4.39% |
| Owned by Institutions (%) | 0.70% |
| Float | 16.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -8.83 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -33.21 |
Financial Efficiency
Return on equity (ROE) is -3,762.21% and return on invested capital (ROIC) is -180.75%.
| Return on Equity (ROE) | -3,762.21% |
| Return on Assets (ROA) | -131.63% |
| Return on Invested Capital (ROIC) | -180.75% |
| Return on Capital Employed (ROCE) | 482.61% |
| Weighted Average Cost of Capital (WACC) | 1.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.00% in the last 52 weeks. The beta is -0.65, so TSXV:SHRX's price volatility has been lower than the market average.
| Beta (5Y) | -0.65 |
| 52-Week Price Change | +82.00% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 26.89 |
| Average Volume (20 Days) | 3,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.87M |
| Pretax Income | -7.36M |
| Net Income | -7.36M |
| EBITDA | -7.86M |
| EBIT | -7.87M |
| Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 148,652 in cash and 3.21 million in debt, with a net cash position of -3.06 million or -0.10 per share.
| Cash & Cash Equivalents | 148,652 |
| Total Debt | 3.21M |
| Net Cash | -3.06M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | -3.10M |
| Book Value Per Share | -0.10 |
| Working Capital | -2.90M |
Cash Flow
| Operating Cash Flow | -6.72M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 19,249 |
| Net Borrowing | -278,250 |
| Free Cash Flow | -6.72M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:SHRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -227.37% |
| Shareholder Yield | -227.37% |
| Earnings Yield | -26.88% |
| FCF Yield | -24.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 27, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jan 27, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |